✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Your cart is empty
Long-Acting IGF-1 Analogue
IGF-1 LR3 is a long-acting analogue of insulin-like growth factor studied in laboratory settings for its role in cell growth signaling and protein synthesis pathways. Research often examines its interaction with IGF-1 receptors, as well as its influence on cellular proliferation, nutrient utilization, and anabolic signaling processes in controlled models.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
IGF-1 LR3 is a synthetic analogue of insulin-like growth factor 1 (IGF-1) modified with an extended amino acid sequence to alter receptor interaction characteristics. It is developed for controlled laboratory research involving IGF-1 receptor signaling systems.
In scientific literature, IGF-1 LR3 is studied in experimental models examining IGF-1 receptor activation pathways, intracellular signaling cascades, and downstream cellular regulatory mechanisms under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
IGF-1 LR3 is a modified form of IGF-1 engineered to alter binding characteristics and receptor interaction dynamics in experimental systems. Research has examined its interaction with IGF-1 receptor pathways and associated intracellular signaling frameworks within controlled laboratory environments.
Preclinical studies evaluate receptor-mediated signaling cascades, cellular growth-related pathways, and regulatory mechanisms under structured research conditions.
Insulin-like growth factor 1 (IGF-1) was identified as a key mediator in growth-related signaling pathways. Subsequent biochemical research led to the development of modified analogues such as IGF-1 LR3, designed to adjust receptor interaction properties for experimental study.
Research expanded into receptor-binding dynamics and intracellular pathway activation models within endocrine and cellular signaling frameworks.
Laboratory investigations into IGF-1 LR3 have focused on IGF-1 receptor activation models and downstream intracellular signaling pathways. Research frameworks evaluate receptor-mediated interaction, kinase activation cascades, and cellular regulatory mechanisms under controlled in vitro and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 1mg of lyophilized IGF-1 LR3. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the peptide preparation. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
MicroRNA‑29‑3p regulates the β‑catenin pathway by targeting IGF1 to inhibit the proliferation of prolactinoma cells. Mol Med Rep 23(6):437.
PubMedIGF-I and IGF-I24-41 but not IGF-I57-70 affect somatic and neurobehavioral development of newborn male mice. Brain Res Bull 36(1):27–32.
PubMedA sensitive radioimmunoassay for somatomedin-C/insulin-like growth-factor I based on synthetic insulin-like growth factor 57-70.
PubMedRelated
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$180.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$10.00
Immune-modulating peptide studied for T-cell signaling and immune system regulatory pathway research
From$70.00
GHRH analog studied for growth hormone regulation and metabolic pathway signaling research
From$95.00
